The All-in-One Screener can be used to find insider buys and sells over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$1,000,000+” and duration to "April 2016."
According to the above filters, the following are recent buys and sells from company insiders in the past week.
On April 21, Baron Capital Enterprise Inc., adviser to Experience Art and Design Inc. (EXAD), bought 55,000,000 shares in the company.
The company has an institutional ownership of 41.36% and insider ownership of 8.10%. It is engaged in the business of producing sculptures and other fine art work from historic moulds for sale to museums, art collectors through galleries and fine art auction houses, precious metals castings and traveling exhibitions.
The stock is now trading with a P/B ratio of 0.26. The price is 90.00% below its 52-week high and 108.33% above its 52-week low.
On April 20, John Nesi, director of Cellectar Biosciences Inc. (CLRB), bought 234,742 shares in the company at the price of $2.12 per share. Since then, the price of the stock has dropped by 10.8% to $1.89.
The company has an insider ownership 30.71% and institutional ownership of 14.65%. It is a pharmaceutical company developing compounds for the treatment and diagnosis of cancer.
The stock is now trading with a P/B ratio of 0.99, and the price is 95.14% below its 52-week high and 3.85% above its 52-week low.
On April 19, Acorn Composite Corp., 10% owner, and Robert W. Roche, 10% owner and director of RVUE Holdings Inc. (RVUE), bought 13,846,154 shares combined in the company at the price of 1 cent per share. Since then, the price of the stock has not changed.
The company has an insider ownership of 13.70% and an institutional ownership of 0.38%. It is an advertising technology company and operates rVue, a demand-side platform for planning, buying and managing Digital Place-Based Networks and Digital Billboards and Signage advertising.
The stock is now trading with a P/S ratio of 1.25. The price is 89.35% below its 52-week high and 226.92% above its 52-week low.
Most important sales of the week
On April 21, Charles R. Schwab, chairman and 10% owner of Charles Schwab Corp. (SCHW), sold 560,000 shares in the company at the price of $29.02 per share. Since then, the price of the stock has risen by 0.4% to $29.13.
The company has an insider ownership of 0.26% and institutional ownership of 77.27%. The company through its subsidiaries is engaged in securities brokerage, banking and related financial services.
During the last 12 months, the price of the stock has dropped by 4% and is now trading with a P/E ratio of 26.51. The price is 18.45% below its 52-week high and 35.43% above its 52-week low.
On April 21, Robert Rosen, director of Heron Therapeutics Inc. (HRTX), sold 200,000 shares in the company at the price of $23.23 per share. Since then, the price of the stock has dropped by 4.3% to $22.22.
The company has an insider ownership of 4.26% and an institutional ownership of 95.31%. It is a specialty pharmaceutical company focused on the development of pharmaceutical products utilizing its proprietary Biochronome(TM) polymer-based drug delivery system, a family of polymers known as poly (ortho esters).
During the last 12 months, the price of the stock has risen by 56% and is now trading with a P/S ratio of 6.79. The price is 47.41% below its 52-week high and 109.62% above its 52-week low.
On April 19, Amy Almsteier, director of Terra Tech Corp. (TRTC), sold 226,799 shares in the company at the price of 56 cents per share. Since then, the price of the stock has dropped by 26.8% to 40 cents.
The company has an institutional ownership of 0.01% and insider ownership of 6.40%. It creates sustainable solutions for food production, indoor cultivation, rare and exotic plants and agricultural research and development.
During the last 12 months, the price of the stock has risen by 141% and is now trading with a P/B ratio of 27.34. The price is 45.00% below its 52-week high and 415.72% above its 52-week low.
On April 19, Thomas Kurian, president-Product Development of Oracle Corp. (ORCL), sold 250,000 shares in the company at the price of $41.33 per share. Since then, the price of the stock has dropped by 0.8% to $40.99.
The company has an institutional ownership of 60.10% and insider ownership of 26.91%. It develops, manufactures, markets, hosts and supports database and middleware software, application software, cloud infrastructure and hardware systems.
During the last 12 months, the price of the stock has dropped by 6% and is now trading with a P/E ratio of 20.18. The price is 9.39% below its 52-week high and 23.72% above its 52-week low.
